Eli Lilly is offering a four-week supply of 2.5-milligram and 5-milligram single-dose vials for $399 and $549, respectively. The list prices for GLP-1 weight loss drugs are typically around $1,000 ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.

Tuesday, Eli Lilly (NYSE:LLY) received continued support from BMO Capital with a reiteration of its Outperform rating and a $1,101.00 price target. The pharmaceutical giant announced the availability ...

Eli Lilly (LLY) has announced it will make lower-priced, single-dose vials of its popular weight-loss treatment Zepound available on telehealth platform Ro. Starting today, consumers can get an ...

Eli Lilly (NYSE: LLY) and Novo Nordisk ... Ozempic, Wegovy, Mounjaro, and Zepound are all administered via injection, but the next wave of GLP-1 agonists is in development, ...

Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Eli Lilly (LLY 1.84%) and Novo Nordisk ... Ozempic, Wegovy, Mounjaro, and Zepound are all administered via injection, but the next wave of GLP-1 agonists is in development, ...

Eli Lilly (NYSE: LLY) and Novo Nordisk ... Ozempic, Wegovy, Mounjaro, and Zepound are all administered via injection, but the next wave of GLP-1 agonists is in development, ...

Eli Lilly's strategic initiatives, such as making Zepound more accessible, are likely to contribute to its continued success and shareholder value. This article was generated with the support of ...